Plus Therapeutics (PSTV) Q1 2026 Earnings
Plus Therapeutics reported Q1 2026 revenue of $1.0M (-2.9% YoY), beat analyst consensus of $974.0K by $54.0K. Diluted EPS came in at $-1.05 (-87.5% YoY), missed the $-0.95 consensus by $0.10.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Plus Therapeutics's Q1 2026 earnings report.
Plus Therapeutics (PSTV) reported Q1 2026 earnings on May 15, 2026 after market close.
Plus Therapeutics reported revenue of $1.0M and diluted EPS of $-1.05 for Q1 2026.
Revenue beat the consensus estimate of $974.0K by $54.0K. EPS missed the consensus estimate of $-0.95 by $0.10.
Compared to the same quarter a year prior, revenue declined 2.9% from $1.1M a year earlier and diluted EPS declined 87.5% from $-0.56.
You can read the 8-K earnings release (0001193125-26-226747) and the 10-Q periodic report (0001193125-26-226978) directly on SEC EDGAR. The filing index links above go to sec.gov.